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Abstract
Background: The EPICOR Asia (long-tErm follow-uP of antithrombotic management patterns In acute CORonary
syndrome patients in Asia) study (NCT01361386) was an observational study of patients hospitalized for acute
coronary syndromes (ACS) enrolled in 218 hospitals in eight countries/regions in Asia. This study examined costs,
length of stay and the predictors of high costs during an ACS hospitalization.
Methods and results: Data for patients hospitalized for an ACS (n = 12,922) were collected on demographics, medical
history, event characteristics, socioeconomic and insurance status at discharge. Patients were followed up at 6 weeks’
post-hospitalization for an ACS event to assess associated treatment costs from a health sector perspective. Primary
outcome was the incurring of costs in the highest quintile by country and index event diagnosis, and identification of
associated predictors. Cost data were available for 10,819 patients. Mean length of stay was 10.1 days. The highest-cost
countries were China, Singapore, and South Korea. Significant predictors of high-cost care were age, male sex, income,
country, prior disease history, hospitalization in 3 months before index event, no dependency before index event,
having an invasive procedure, hospital type and length of stay.
Conclusions: Substantial variability exists in healthcare costs for hospitalized ACS patients across Asia. Of concern is the
observation that the highest costs were reported in China, given the rapidly increasing numbers of procedures in
recent years.
Trial registration: NCT01361386.
Keywords: Acute coronary syndrome, Asia, Health insurance, Costs, Hospitalization
Background
Ischemic heart disease is associated with a substantial
healthcare burden worldwide, in terms of both deaths
and disability-adjusted life years [1], while the costs of
treating acute coronary syndromes (ACS) also represent a
major burden for healthcare systems globally [2–6]. With
the increasing prevalence of lifestyle-related chronic-
disease risk factors, increasing healthcare costs, techno-
logical innovation, and growing consumer and patient
expectations regarding access to twenty-first century
healthcare, it is expected this burden will likely continue
to increase [5]. This will have implications for the future
financial sustainability of healthcare systems globally.
These pressures are particularly pronounced in low-
and middle-income countries in Asia where large-scale
policies are underway or in planning; notably, in India
and China to achieve universal coverage through the
expansion of financial coverage for treatments to previously
under-served populations. Such reforms, while critical in
promoting social protection and equity of access to
healthcare, come with significant resource requirements
and will inevitably magnify future health sector financing
challenges.
In addressing issues of cost and financial sustainability,
understanding of the factors that drive variation in resource
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use is important, particularly those factors that contribute
to higher treatment costs. Notably, only very few studies
have examined the factors associated with variation in
treatment costs for ACS. Evidence from the US, comparing
inpatient resource use for ACS in patients who died in hos-
pital with that for a surviving ACS cohort, indicated that
inpatient mortality for ACS is associated with a 47% greater
duration of hospital stay along with an incremental cost of
around US$43,000 [7]. Similarly, in a study conducted in
Italy, which followed up patients for 12 months’ post-
hospitalization for ACS, patients who died of a cardio-
vascular event had an average cost of around €16,000
compared with an average cost of around €11,000 for
the entire ACS cohort [8]. In China, a small study in a
single hospital in Shandong found that increased age was as-
sociated with increased treatment costs and poorer clinical
outcomes [9]. In a study in the US of over 12,000 patients
with ACS, which compared those with and without diabetes,
the presence of diabetes was reported to incur significant
additional hospitalization costs of $32,577 versus no diabetes
$29,150 [10]. Although evidence from such studies helps to
clarify how resource use varies for patients with differing
clinical presentations, the implications for policy are limited
insofar as they reinforce the well-acknowledged relationship
between more severe and complex illness and higher health-
care costs.
Investigation into the broader socioeconomic and regional
health systems factors that influence costs is generally
limited. Notably, however, a study in India using national
administrative and household survey data reported that
costs of hospitalization for cardiovascular disease were
significantly higher in private health centers, in patients of
high-fertility status, and in those of high socioeconomic
status [11]. Studies of this kind, which examine broader
healthcare systems and socioeconomic drivers of healthcare
costs, provide potential policy lessons by addressing dispar-
ities in costs that reflect possible inefficiencies in healthcare
systems, and are thus amenable to policy intervention.
In this study we assessed hospitalization costs associated
with treating ACS patients across eight countries/regions
in Asia: China, Hong Kong, India, Malaysia, Singapore,
South Korea, Thailand, and Vietnam. The aim was to
highlight variations in care costs across different healthcare
settings and by different categories of ACS (ST-eleva-
tion myocardial infarction [STEMI], non-STEMI
[NSTEMI] and unstable angina [UA]), and to determine
the clinical, socioeconomic, and healthcare system factors
that predict whether patients incur a level of treatment
cost equivalent to the highest quintile by country and type
of ACS.
Methods
The EPICOR Asia (long-tErm follow-uP of antithrom-
botic management patterns In acute CORonary
syndrome patients in Asia) study (NCT01361386; regis-
tration, May 26, 2011), was a prospective, multinational,
observational, cohort study of patients hospitalized for
ACS enrolled in 218 hospitals in eight countries/regions
in Asia [12]. These countries represent a combination
of high- (Singapore, Hong Kong, Republic of Korea),
upper-middle (China, India, Malaysia), and lower-middle
(India, Vietnam) income settings. EPICOR Asia recruited
consecutive patients hospitalized for ACS within 48 h of
symptom onset and who were discharged with a final
diagnosis of STEMI, NSTEMI, or UA, with
2-yearfollow-up. Data collection occurred between 2011
and 2014.
The study was conducted in compliance with the princi-
ples of the Declaration of Helsinki, International Confer-
ence on Harmonization Good Clinical Practice guidelines
and applicable legislation on non-interventional studies
in participating countries and regions. The protocol,
including the informed consent form, was approved in
writing by the applicable ethics committee of the partici-
pating centers in accordance with local regulations in each
country. The ethics committee also approved any other
non-interventional study documents in accordance with
local regulations. A list of participating centers is provided
in Additional file 1: Table S1. Patients provided written
informed consent at discharge and completed a contact
order form agreeing to be contacted for regular follow-up
interviews post-discharge.
Data were collected from 12,922 patients on demo-
graphics, medical history, event characteristics, and so-
cioeconomic and insurance status at discharge. Patients
were followed up at 6 weeks following hospitalization
for the index event in regard to treatment course. Costs
associated with hospitalization were estimated from a
health sector perspective based on health system pay-
ments for individual items at each specific hospital. Such
payments reflect the outlay required of payers and are
therefore of primary relevance from a policy standpoint.
Costs were converted into US dollars at the prevailing
exchange rates (see footnote to Table 2). These have not
been converted into international dollars although pre-
vailing purchasing power parities (PPPs) are presented
to enable the reader to make such a conversion. In spite
of potentially skewed distributions, mean costs were re-
ported in accordance with economic theory which
deems that the arithmetic mean (unlike the median) best
informs resource allocation given a budgetary constraint
[13–17].
The primary outcome was whether a patient incurred
costs in the highest quintile for their specific country and
index event diagnosis. This type of binary outcome, stan-
dardized against country and condition-specific norms,
facilitated the pooling of data from multiple countries with
differences in living standards and cost structures.
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We assessed the association between the outcomes
variable and several demographic, socioeconomic, health
and clinical systems variables through univariate analyses.
These variables included age, sex, smoking status, income
(defined by country-specific quintiles based on country-
specific income distributions, with quintile 1 representing
the lowest income group, and quintile 5 the highest),
country, place of residence (rural versus metropolitan), in-
surance status, cardiovascular disease history, hospitalization
in the 3 months prior to the index event, dependence before
the index event, index event medical management (invasive,
non-invasive or unknown), type of hospital (regional/
community/rural, non-university general hospital, university
general hospital, other type of hospital/clinic), number of
beds within the facility, and length of stay. A multivariable
logistic regression model was constructed using stepwise
selection, forcing in a variable of interest – health insurance
status. A conditional binary regression model [18] to con-
duct a matched analysis was not used because the objective
in this study was not to estimate a treatment effect.
Analyses were undertaken using SAS® v8.2 or later
(SAS Institute, Cary, USA).
Results
Cost data were available for 10,819 participants; data
from Malaysia (n = 42 patients) were excluded as costs
were incorrectly recorded. Overall, 71% of participants
were from China and 21% from India. Hong Kong,
South Korea, Thailand, and Vietnam comprised between
1.2–2.3% of participants, with Singapore representing
the fewest participants (0.6%).
Participant mean age was 60 years, 77% were males
and 33% were current smokers compared with 20%
former smokers, and 40% who had never smoked. Most
participants were concentrated in the second (42%) and
third (25%) income quintiles. Quintile 1 comprised less
than 1% of participants, quintile 4 had 2% and quintile 5
had 24% (Table 1).
The majority (65%) of participants were resident in
metropolitan areas compared with 35% in rural areas;
83% of participants had health insurance; 28% had some
cardiovascular disease history; 7% had been hospitalized
in the 3 months before the index event; 13% had some
degree of dependence before the index event; and 83%
underwent an invasive procedure during hospitalization.
In terms of hospital type, 5% were admitted to a regional/
community/rural hospital, 23% to a non-university general
hospital, 56% to a university general hospital, and 17% to a
‘other’ type of hospital or clinic. The mean number of
beds was 1312, and mean length of stay was 10.1 days,
with little difference between STEMI (10.3 days), NSTEMI
(10.2 days) and UA (9.8 days) (Table 1).
When compared in US dollars, the highest-cost countries
were China (STEMI mean cost = $7790; NSTEMI = $7450;
UA= $6585), Singapore ($6978; $4910; $3394), the Republic
of Korea ($4300; $4621; $3552), and Thailand ($4427;
$3321; $2008); across the three index-event types, UA
generally represented the lowest-cost category except in
India where it was the highest, albeit modestly (Fig. 1).
In Hong Kong, all emergency admissions for ACS are
subsidised by the Government and although the real
cost incurred is not clear, health system payments to
the patient are generally low. In terms of invasive inter-
ventional procedures, the highest costs were associated
with (in descending order) coronary artery bypass graft,
percutaneous coronary intervention (PCI) with one
drug-eluting stent, PCI with one bare metal stent, and
angiography; the costs for these procedures being highest
in China, Hong Kong, Singapore, and Thailand (Table 2;
also, conversion of these costs based on purchasing power
parities (PPP) into international dollars is provided in
Additional file 1: Table S2). Univariate analyses indicated
that high-cost utilization was significantly associated with
income, hospitalization in the 3 months prior to the index
event, degree of dependence before the index event,
index-event medical management, length of stay, sex, type
of hospital and disease history (Table 3).
In controlling for all these variables at once, a multivariate
analysis indicates the significant predictors of high-cost care
were age (odds ratio [OR] = 1.10 per 10-year increment),
being male (OR = 1.17), income (quintile 2 versus 5: OR =
0.76), prior disease history (OR = 1.25), hospitalization in
the 3 months prior to index event (OR = 1.48), no depend-
ency prior to index event (OR = 1.96), having an invasive
procedure (OR = 5.48), hospital type (community versus
university general: OR = 1.74), country (Hong Kong versus
China: OR = 1.92; India versus China: OR = 2.54; Thailand
versus China: OR = 1.52) and length of stay (OR = 1.06 per
day) (Table 4).
Discussion
This study in more than 10,000 participants represents
one of the largest prospective cost analyses of ACS and
one of only few such analyses to provide cross-country
comparisons. We found substantial variations across
countries/regions and index diagnosis in healthcare costs
incurred by patients during hospitalization for treatment
of an ACS event. This is perhaps to be expected given the
milieu of high, upper-middle and lower-middle income
countries included in EPICOR Asia. What seems surpris-
ing is that the cost of treating ACS appeared relatively
high in China across all three index-event types, exceeding
those recorded for high-income countries/regions such as
Singapore, the Republic of Korea, and Hong Kong. Inter-
estingly, in contrast to Hong Kong and Singapore, costs in
China were generally similar across all three index-event
types. This suggests stratification of patients may not
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Table 1 Baseline characteristics by final diagnosis of index event – all patients with cost data
STEMI (n = 5478) NSTEMI (n = 2030) UA (n = 3311) Total (n = 10,819)
Age, mean (SD) 58.5 (11.7) 61.9 (11.95) 61.4 (10.44) 60.0 (11.48)
Male, n (%) 4532 (82.7) 1520 (74.9) 2247 (67.9) 8299 (76.7)
Smoker, n (%)
Current 2197 (40.1) 649 (32.0) 742 (22.4) 3588 (33.2)
Former 964 (17.6) 398 (19.6) 775 (23.4) 2137 (19.8)
Never 1896 (34.6) 855 (42.1) 1602 (48.4) 4353 (40.2)
Unknown 421 (7.7) 128 (6.3) 192 (5.8) 741 (6.8)
Income, n (%)
Quintile 1 14 (0.3) 21 (1.0) 18 (0.5) 53 (0.5)
Quintile 2 2352 (42.9) 849 (41.8) 1342 (40.5) 4543 (42.0)
Quintile 3 1253 (22.9) 471 (23.2) 965 (29.1) 2689 (24.9)
Quintile 4 70 (1.3) 61 (3.0) 31 (0.9) 162 (1.5)
Quintile 5 1271 (23.2) 463 (22.8) 805 (24.3) 2539 (23.5)
Country, n (%)
China 3716 (67.8) 1234 (60.8) 2754 (83.2) 7704 (71.2)
Hong Kong 75 (1.4) 45 (2.2) 5 (0.2) 125 (1.2)
India 1341 (24.5) 527 (26.0) 415 (12.5) 2283 (21.1)
Singapore 25 (0.5) 36 (1.8) 4 (0.1) 65 (0.6)
South Korea 101 (1.8) 70 (3.4) 76 (2.3) 247 (2.3)
Thailand 124 (2.3) 81 (4.0) 30 (0.9) 235 (2.2)
Vietnam 96 (1.8) 37 (1.8) 27 (0.8) 160 (1.5)
Place of residence, n (%)
Rural 2088 (38.1) 624 (30.7) 1067 (32.2) 3779 (34.9)
Metropolitan 3390 (61.9) 1406 (69.3) 2244 (67.8) 7040 (65.1)
Insurance status, n (%)
Yes 4396 (80.2) 1620 (79.8) 2950 (89.1) 8966 (82.9)
No 1082 (19.8) 410 (20.2) 361 (10.9) 1853 (17.1)
Disease history, n (%) 1008 (18.4) 630 (31.0) 1437 (43.4) 3075 (28.4)
Myocardial infarction 354 (6.5) 247 (12.2) 421 (12.7) 1022 (9.4)
Prior PCI 201 (3.7) 173 (8.5) 455 (13.7) 829 (7.7)
Prior CABG 43 (0.8) 39 (1.9) 70 (2.1) 152 (1.4)
CAG diagnostic for CAD 233 (4.3) 216 (10.6) 606 (18.3) 1055 (9.8)
Chronic angina 484 (8.8) 299 (14.7) 1018 (30.7) 1801 (16.6)
Heart failure 63 (1.2) 71 (3.5) 135 (4.1) 269 (2.5)
Atrial fibrillation 47 (0.9) 45 (2.2) 62 (1.9) 154 (1.4)
TIA/stroke 212 (3.9) 101 (5.0) 166 (5.0) 479 (4.4)
Peripheral vascular disease 24 (0.4) 24 (1.2) 41 (1.2) 89 (0.8)
Chronic renal failure 59 (1.1) 70 (3.4) 38 (1.1) 166 (1.5)
Hospitalization in 3 months prior to index event, n
(%)
206 (3.8) 126 (6.2) 458 (13.8) 790 (7.3)
Dependence degree (need of help for daily activities) prior to index event, n (%)
Some dependence 715 (13.1) 318 (15.7) 367 (11.1) 1400 (12.9)
No dependence 4601 (84.0) 1659 (81.7) 2826 (85.4) 9086 (84.0)
Unknown 162 (3.0) 53 (2.6) 118 (3.6) 333 (3.1)
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have been optimal, with patients at high- and lower-risk
variably receiving high-level interventional therapy, and of
variable cost. This may be compounded by inaccurate re-
cording as to whether percutaneous transluminal coronary
angioplasty was provided with or without stenting. Further
detailed study is required to establish the multifarious fac-
tors underlying the apparent high costs of treatment in
China and alleviate any concerns to decision makers given
the increasing burden of ACS and growing proliferation of
treatment. For example, between 2007 and 2011, there
was a virtual doubling in the number of PCI procedures
performed from 180,000 to 330,000 [19].
The finding that age is a positive predictor of high
cost is consistent with potentially greater complexity
and severity of illness, some of which may not have
been captured and thus controlled for in the model.
This is perhaps further evidenced by the positive asso-
ciation between hospitalization in the 3 months prior
to the index event and high costs. Similar findings for
male sex are consistent with a study in Italy where
costs incurred by men were significantly greater than
that for women, irrespective of index-event type [8].
Reports that women who present with ACS may be
evaluated less intensively than men, may go some way
towards explaining this [20].
The findings reported here also provide evidence of a
potential income effect in that patients on relatively high
income appear more likely to be categorized as highest
cost. Odds ratios relative to income quintile 5 of 0.45 for
quintile 1; 0.76 for quintile 2; 0.97 for quintile 3; 0.80 for
quintile 4 (although only statistically significant in rela-
tion to quintile 2), ostensibly indicate a pattern in which
the odds of incurring high costs increase with income.
Such a finding, again, accords with expectations that
wealthier patients will seek and have access to higher-cost
treatments.
The findings that longer length of stay and having an
invasive procedure (versus non-invasive medical manage-
ment) were both positively associated with odds of incur-
ring high costs is consistent with expectations and reflects,
perhaps obviously, resource needs associated with longer
treatment duration and need for an invasive procedure.
Less intuitive is the finding that those patients who re-
quired no help with daily activities prior to hospitalization
for their index condition (“no dependence”) had signifi-
cantly higher odds of being in the highest-cost category.
Here, it is possible that patients with dependency at
Table 1 Baseline characteristics by final diagnosis of index event – all patients with cost data (Continued)
STEMI (n = 5478) NSTEMI (n = 2030) UA (n = 3311) Total (n = 10,819)
Index event medical management, n (%)
Invasive 4713 (86.0) 1598 (78.7) 2612 (78.9) 8923 (82.5)
Non-invasive 724 (13.2) 422 (20.8) 617 (18.6) 1763 (16.3)
Unknown 41 (0.7) 10 (0.5) 82 (2.5) 133 (1.2)
Type of hospital, n (%)
Regional/community/rural hospital 296 (5.4) 111 (5.5) 76 (2.3) 483 (4.5)
Non-university general hospital 1269 (23.2) 368 (18.1) 792 (23.9) 2429 (22.5)
University general hospital 2931 (53.5) 1074 (52.9) 2092 (63.2) 6097 (56.4)
Other type of hospital/clinic 982 (17.9) 477 (23.5) 351 (10.6) 1810 (16.7)
Number of beds, mean (95% CI) 1307.1 (1280.0,
1334.2)
1223.1 (1181.9,
1264.3)
1374.5 (1338.6,
1410.5)
1311.9 (1292.7,
1331.2)
Length of stay, mean (95% CI) 10.3 (10.2, 10.5) 10.2 (9.9, 10.6) 9.8 (9.6, 10.0) 10.1 (10.0, 10.3)
CABG Coronary artery bypass graft, CAD Coronary artery disease, CAG Coronary angiogram, CI Confidence interval, NSTEMI Non-ST-elevation myocardial infarction,
PCI Percutaneous coronary intervention, STEMI ST-elevation myocardial infarction, TIA Transient ischemic attack, UA Unstable angina
Fig. 1 Mean cost (US$) by country and index event.
NSTEMI non-ST-elevation myocardial infarction, STEMI ST-elevation
myocardial infarction, UA unstable angina
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baseline would have the ongoing support of a “carer” to
rely on. The potential lack of such support for patients
without dependency at baseline may have led to greater
costs due to a greater need for in-hospital rehabilitation
and extensive discharge planning.
Another ostensibly unexpected observation was that
the odds of incurring high-cost treatment, relative to
those encountered in patients admitted to a university
general hospital, were higher for those patients admitted
to all “other” categories of hospital, e.g. regional/com-
munity/rural hospitals, non-university general hospitals
and other type of clinics. Here, it is possible that the
multivariable analysis used in this study effectively
controlled for factors implicated in higher costs seen in
teaching (university) hospitals, such as size of facility,
treatment mode, disease history and length of stay.
Our findings suggest, therefore, that the independent
effect of university status of a hospital was to lower
costs, very likely associated with efficiency and an
established degree of expertise in such centers.
The lack of significant association between insurance
status and high-cost care may allay potential concerns
about the inflationary effects of national programs to
expand insurance coverage, e.g. due for instance to
incentives created by a third-party payer for providers to
overcharge/over-service (provider moral hazard) and
patients to overuse (patient moral hazard) [21]. Although
this study focuses only on ACS patients, the findings of
Table 3 Model-based point estimates for high-cost healthcare expenditurea using logistic models – univariate analysis (excluding
Malaysia)
Factor Odds ratio 95% CI P value
Age, per 10-year increment 1.04 0.99, 1.08 0.0925
Sex, male versus female 1.18 1.06, 1.33 0.0038
Income (versus quintile 5) < 0.0001
Quintile 1 0.45 0.19, 1.06
Quintile 2 0.76 0.67, 0.85
Quintile 3 0.97 0.85, 1.11
Quintile 4 0.80 0.53, 1.20
Health insurance, yes versus no 1.02 0.90, 1.16 0.7074
Residence, rural versus non-rural 1.02 0.92, 1.12 0.7516
Smoker (versus never) 0.2418
Current 0.92 0.83, 1.03
Former 1.02 0.89, 1.15
Disease history, yes versus no 1.15 1.04, 1.28 0.0068
Hospitalization in the 3 months prior to index event, yes versus no 1.37 1.16, 1.62 0.0002
Dependence degree before index event, none versus some 1.74 1.48, 2.05 < 0.0001
Index event medical management, invasive versus non-invasive 4.62 3.78, 5.64 < 0.0001
Type of hospital (versus UGH) 0.0030
Regional/community/rural hospital 0.92 0.72, 1.17
Non-UGH 1.13 1.01, 1.27
Other type of hospital/clinic 1.24 1.09, 1.40
Number of beds 1.00 1.00, 1.00 0.5995
Length of stay 1.04 1.03, 1.05 < 0.0001
Country (versus China) 0.8569
Hong Kong 1.00 0.64, 1.56
India 1.09 0.97, 1.23
Singapore 0.91 0.48, 1.70
South Korea 1.00 0.72, 1.36
Thailand 1.00 0.72, 1.38
Vietnam 0.96 0.65, 1.43
UGH University general hospital, CI Confidence interval
ahigh cost defined as the top quintile within a country
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this study found no evidence of an inflationary impact
associated insurance coverage. Further country-specific
research is needed to determine whether the roll out of
social insurance programs will increase costs to any
significant degree.
There were several limitations in the present study.
First, inclusion only of patients alive and followed up at
6 weeks might suggest a possible survivor bias to the
findings. As mentioned, earlier studies have reported
in-hospital mortality to be associated with higher costs,
suggesting our estimates of average costs may have been
underestimated. In addition, the costs examined in this
study reflect only health system cost whereas a broader
societal perspective would have considered costs to
households and the community associated with indirect
loss of income and reduced productivity. Also, the costs
included in this analysis were confined to hospitalization
for the index condition and excluded costs of potential
re-hospitalizations for ACS; in the US, such costs have
been estimated at over 30% [22], suggesting there are
significant costs associated with ACS outside of the
scope of this analysis. Furthermore, the costs of sub-acute
follow-up care were not included. These may vary across
countries due to differences in treatment norms, funding
models and other health system characteristics. Despite
these potential limitations in capturing the high costs to
health systems associated with ACS, the study highlights
the major policy challenges associated with a high burden
of illness in Asia. Some countries in this analysis were
represented by a relatively small number of participants,
thus precluding detailed country-specific analyses. Thus,
the way in which the primary outcome for this study was
specified (i.e. occurrence of cost in the highest quintile
specific to each country and index condition) served as a
standardized outcome that facilitated the pooling of data
across all countries. An alternative approach would have
been to adjust for differences in purchasing power by con-
verting into international dollars; however, the problem
with such a strategy is that costs reported in international
dollars lack meaning for local policy makers since they do
Table 4 Model-based point estimates for high-cost healthcare expenditurea using logistic models – multivariate analysis (excluding
Malaysia)
Factor Odds ratio 95% CI P value
Age, per 10-year increment 1.10 1.05, 1.16 < 0.0001
Sex, male versus female 1.17 1.02, 1.33 0.0224
Income (versus quintile 5) < 0.0001
Quintile 1 0.43 0.15, 1.19
Quintile 2 0.76 0.67, 0.86
Quintile 3 0.96 0.83, 1.11
Quintile 4 0.74 0.45, 1.23
Health insurance, yes versus no 1.11 0.89, 1.38 0.3686
Disease history, yes versus no 1.25 1.11, 1.41 0.0002
Hospitalization in the 3 months prior to index event, yes versus no 1.48 1.23, 1.77 < 0.0001
Dependence degree before index event, none versus some 1.96 1.60, 2.40 < 0.0001
Index event medical management, invasive versus non-invasive 5.48 4.34, 6.92 < 0.0001
Type of hospital (versus UGH) 0.0016
Regional/community/rural hospital 1.74 1.25, 2.41
Non-UGH 1.13 0.99, 1.29
Other type of hospital/clinic 0.97 0.79, 1.19
Length of stay 1.06 1.04, 1.06 < 0.0001
Country (versus China) < 0.0001
Hong Kong 1.92 1.04, 3.53
India 2.54 1.98, 3.25
Singapore 1.58 0.77, 3.24
South Korea 1.21 0.76, 1.95
Thailand 1.52 1.05, 2.20
Vietnam 0.90 0.57, 1.42
UGH University general hospital
aDefined as the top quintile within a country
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not reflect actual budgetary implications (nevertheless the
conversions are provided in Additional file 1: Table S2 for
reference). The inclusion of hospital length of stay as an
explanatory variable and the likelihood of it being highly
correlated with cost is a potential weakness in the
modelling [23], as we may not be able to identify factors
that affect the cost through the hospital length of stay.
However, it is an important variable of interest and its
inclusion is justified as it allows us to estimate the direct
effect of other factors included in the model. Finally, with-
out accounting for clustering in the analysis, variance and
confidence intervals could be slightly underestimated.
However, in international studies of this kind, it is conven-
tional that such adjustments are not made.
Conclusion
The present analysis highlights the drivers of high-cost
treatment for ACS in Asia. It represents an advance in
this area by examining factors beyond the clinical drivers
of costs. The study further identifies health-system factors
including hospital type, and health insurance and socioeco-
nomic status, providing evidence to policy makers of the
financial implications of current and future reforms;
notably programs in Asia to expand health insurance
coverage to underserved populations. The value of
prevention programs in avoiding hospitalizations for
ACS is also considered to highlight population groups
(e.g. men, high-income groups, and uninsured) in whom
effective prevention may yield the greatest financial
savings.
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